JP Morgan Chase’s TG Therapeutics TGTX Stock Holding History

JP Morgan Chase’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-24,000	Closed	-$864K	–	7723
2025 Q2	$864K	Hold	24,000	–	–	﹤0.01%	4471
2025 Q1	$946K	Hold	24,000	–	–	﹤0.01%	4391
2024 Q4	$722K	Buy	+24,000	New	+$689K	﹤0.01%	4840
2021 Q4	–	Sell	-375,000	Closed	-$12.5M	–	6952
2021 Q3	$12.5M	Hold	375,000	–	–	﹤0.01%	2193
2021 Q2	$14.5M	Buy	+375,000	New	+$14.7M	﹤0.01%	2102
2019 Q2	–	Sell	-185,700	Closed	-$1.49M	–	6012
2019 Q1	$1.49M	Buy	+185,700	New	+$1M	﹤0.01%	3534

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

JP Morgan Chase's TGTX Position: Q2 2026 in Review

JP Morgan Chase increased its TG Therapeutics (TGTX) stake by 171% in Q2 2026, buying an estimated $10.5M and bringing the position to 407,499 shares worth $23.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2104.

JP Morgan Chase first reported a position in TGTX in Q2 2013 and has held it in 46 quarters since. The position peaked at $23.2M in Q1 2025. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

JP Morgan Chase held 407,499 shares of TG Therapeutics worth $23.1M as of Q2 2026.
JP Morgan Chase bought 256,976 TG Therapeutics shares in Q2 2026, an estimated $10.5M.
TG Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2104 holding.
JP Morgan Chase first reported a position in TG Therapeutics in Q2 2013 and has held it in 46 quarters since.
JP Morgan Chase's TG Therapeutics position peaked at $23.2M in Q1 2025.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.